FREE COMMUNICATION 3

11.45-13.15   FORUM
     

ADPKD - Clinical outcome studies

 

Chairs: Ron T. Gansevoort, Groningen, The Netherlands
            Vicente E. Torres, Rochester, USA
  
FREE COMMUNICATIONS 
 
* SO011
THE PRO-PKD SCORE, A NEW ALGORITHM TO PREDICT RENAL OUTCOME IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Emilie Cornec-Le Gall1,2, Maryvonne Hourmant3, Marie-Pascale Morin4, Christophe Charasse5, Eric Renaudineau6, Bassem Wehbe7, Theophile Sawadogo8, Katell Goulesque9, Philippe Jousset10, Regine Perrichot11, Marie-Paule Guillodo12, GENKYST Study Group, Marie-Pierre Audrézet1,13, Claude Férec1,2,13, Yannick Le Meur1,2 1CHRU Brest, France, Brest, France, 2Univ Bretagne Occidentale, Brest, France, 3CHU Nantes, Nantes, France, 4Chu Rennes, Rennes, France, 5CH Saint Brieuc, Saint Brieuc, France, 6CH Saint Malo, Saint Malo, France, 7CH Quimper, Quimper, France, 8CH Lorient, Lorient, France, 9SBRA Brest, Brest, France, 10CH Pontivy, Pontivy, France, 11CH Vannes, Vannes, France, 12Aub Brest, Brest, France, 13INSERM1078, Brest, France
  
SO012
MAGNETIC RESONANCE PHASE-CONTRAST MEASUREMENT OF RENAL BLOOD FLOW IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. FEASIBILITY IN ALL STAGES OF THE DISEASE.
Edwin M. Spithoven, Esther Meijer, Chris Borns, Wendy E. Boertien, Peter Kappert, Marcel J.W. Greuter, Eric Van Der Jagt, Paul E. De Jong, Carlo A.J.M. Gaillard, Ron T. Gansevoort UMC Groningen, Groningen, Netherlands
  
SO013
INTERVENTIONS FOR RETARDING THE PROGRESSION OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): A SYSTEMATIC REVIEW AND META-ANALYSIS
Davide Bolignano1, Suetonia Palmer2, Marinella Ruospo3,4,5, Carmine Zoccali1, Jonathan Craig6,7, Giovanni Strippoli3,4,5 1CNR-National Council of Research, Reggio Calabria, Italy, 2Univ Otago, Christchurch, New Zealand, 3Univ Bari, Bari, Italy, 4Mario Negri Sud Consortium, Bari, Italy, 5Diaverum Medical Scientific Office, Lund, Sweden, 6School of Public Health, Univ Sydney, Sydney, Australia, 7Cochrane Renal Group, Centre for Kidney Research, Children’s Hosp Westmead, Westmead, Australia 
    
SO014
URINE OSMOLALITY AND OUTCOME IN ADPKD: RESULTS FROM THE TEMPO 3:4 TRIAL.
O. Devuyst1, A. B. Chapman2, R. T. Gansevoort3, J. J. Grantham4, E. Higashihara5, R. D. Perrone6, V. E. Torres7, H. B. Krasa8, J. Ouyang8, S. Shoaf8, F. S. Czerwiec8 1UZH, Zurich, Switzerland, 2Emory, Atlanta, AL; 3UGMC, Groningen, Netherlands, 4Univ Kansas, Kansas City, KS; 5Kyorin Univ, Mitaka, Japan, 6Tufts MC., Boston, MA; 7Mayo, Rochester, MN; 8Otsuka PDC, Rockville, MD 
  
* SO016
TOLVAPTAN-TREATMENT OF ADPKD CONFERS PERSISTENT EGFR IMPROVEMENT: RESULTS FROM THE TEMPO 4:4 EXTENSION TRIAL
Vicente E Torres1, Arlene B Chapman2, Olivier Devuyst3, Ronald T Gansevoort4, Eiji Higashihara5, Ronald D Perrone6, John Ouyang7, Susan E Shoaf7, Ann Dandurand8, Robert D McQuade8, Frank S Czerwiec7 1Mayo Clinic, Rochester, MN; 2Emory Univ Medical Center, Atlanta, GA; 3Univ Zurich, Zurich, Switzerland, 4Univ Medical Center Groningen, Groningen, Netherlands, 5Kyorin Univ School of Medicine, Tokyo, Japan, 6Tufts-New England Medical Center, Boston, MA; 7Otsuka PDC, Rockville, MD; 8Otsuka PDC, Princeton

   

back to the timetable